Nathan F Moore - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Nathan F Moore

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Behavioral Healthcare|July 30, 2010

Improving the revenue cycle processNathan F Moore

International Journal of Molecular Sciences|September 9, 2020

Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic EnvironmentDaniel T Doty, Julia Schueler, Vienna L Mott, et al.

Oncotarget|September 18, 2014

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastomaNathan F Moore, Anna M Azarova, Namrata Bhatnagar, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Behavioral Healthcare|July 30, 2010

Improving the revenue cycle processNathan F Moore

International Journal of Molecular Sciences|September 9, 2020

Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic EnvironmentDaniel T Doty, Julia Schueler, Vienna L Mott, et al.

Oncotarget|September 18, 2014

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastomaNathan F Moore, Anna M Azarova, Namrata Bhatnagar, et al.

Pageof 1